$1.323.65%-0.05

Femasys Inc (FEMY)

Date: O: H: L: C: Vol:

Femasys Inc 주식 (FEMY) 회사 개요

770-500-3910

3950 JOHNS CREEK COURT, SUWANEE, USA

최신 SEC 제출 서류

X에서 FEMY에 대한 토론

Femasys Inc 주식(FEMY) 업그레이드 및 다운그레이드

날짜	액션	분석자	등급 변경
2025-11-20	개시	Laidlaw	Buy

Femasys Inc (FEMY) 재무 분석

기간	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
기간 종료일	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	2.29	1.63	1.07	1.21	1.18
Cost of revenue USD (M)	0.87	0.54	0.38	0.44	0.37
Gross profit USD (M)	-	-	0.69	0.76	0.81
Research and development USD (M)	7.58	8.22	7.21	5.81	4.08
Operating expenses USD (M)	19.01	18.87	15.20	12.36	9.15
Operating income USD (M)	-17.59	-17.79	-14.51	-11.60	-8.34
Income before tax USD (M)	-18.63	-18.81	-14.24	-11.39	-7.53
Income tax expense USD (M)	0.00	0.01	0.00	0.01	0.00
Net income USD (M)	-18.63	-18.82	-14.25	-11.39	-7.54
Basic EPS USD/shares	-0.47	-0.85	-0.93	-0.96	-1.12
Diluted EPS USD/shares	-0.47	-0.85	-0.93	-0.96	-1.12
Basic weighted shares shares (M)	39.55	22.27	15.38	11.82	6.71
Diluted weighted shares shares (M)	39.55	22.27	15.38	11.82	6.71

Femasys Inc 주식 (FEMY) 내부자 거래

Mifek Jeffrey GeraldAug 07 '26
Chief Clinical-Medical Affairs
거래
Buy
비용
$3.20
#주식
3,125
가치 ($)
10,000
#주식 총계
3,125
Sipos Jeremy AlexanderAug 07 '26
Chief Technology Officer
거래
Buy
비용
$3.20
#주식
3,125
가치 ($)
10,000
#주식 총계
3,125
Canning John CharlesAug 07 '26
Chief Operating Officer
거래
Buy
비용
$3.20
#주식
4,375
가치 ($)
14,000
#주식 총계
4,375
Elefant DovAug 07 '26
Chief Financial Officer
거래
Buy
비용
$3.20
#주식
15,625
가치 ($)
50,000
#주식 총계
15,625
Lee-Sepsick KathyAug 07 '26
Chief Executive Officer
거래
Buy
비용
$3.20
#주식
15,625
가치 ($)
50,000
#주식 총계
15,625

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Mifek Jeffrey Gerald	Chief Clinical-Medical Affairs	Aug 07 '26	Buy	$3.20	3,125	10,000	3,125
Sipos Jeremy Alexander	Chief Technology Officer	Aug 07 '26	Buy	$3.20	3,125	10,000	3,125
Canning John Charles	Chief Operating Officer	Aug 07 '26	Buy	$3.20	4,375	14,000	4,375
Elefant Dov	Chief Financial Officer	Aug 07 '26	Buy	$3.20	15,625	50,000	15,625
Lee-Sepsick Kathy	Chief Executive Officer	Aug 07 '26	Buy	$3.20	15,625	50,000	15,625

Femasys Inc 주식(FEMY)의 최신 뉴스

Femasys Inc (FEMY)

Femasys Inc 주식 (FEMY) 회사 개요

시가총액

매출

순이익

현금흐름

주당 순 이익

Femasys Inc 주식(FEMY) 업그레이드 및 다운그레이드

Femasys Inc (FEMY) 재무 분석

Femasys Inc 주식 (FEMY) 내부자 거래

Femasys Inc 주식(FEMY)의 최신 뉴스

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs - GlobeNewswire Inc.

Empery Asset Management Reports 5.6% Ownership Stake in Femasys Inc. - Kalkine Media

A fund manager reports a passive 468,750-share stake in Femasys (FEMY). - Stock Titan

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control - GlobeNewswire Inc.

Form 4 Femasys Inc For: 29 September By Investing.com - Investing.com Nigeria

Form 4 Femasys Inc For: 29 September By Investing.com - Investing.com UK

Femasys Inc (NASDAQ: FEMY) Share Price, FEMY Stock News, FEMY Share Price & Updates - Kalkine

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Yahoo Finance

Femasys Company Profile & Introduction - Moomoo

Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus

Femasys - Files For Resale Of Up To 28,124,997 Shares Of Common Stock - SEC Filing - TradingView

Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan

Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research

Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan

Femasys (FEMY) Stock News & Analysis - TechStock²

Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India

Femasys partners with UNC Health for fertility services By Investing.com - Investing.com Canada

Femasys partners with UNC Health for fertility services By Investing.com - Investing.com UK

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - The Manila Times

Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the Day - Value Stock Ideas - vinanet.vn

Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the Day - Composite Profile - dars.gov.et

Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest Reading - Volume Dry Up - vinanet.vn

Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest Reading - Hagopian Line - siam.in

Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest Trading - Volatility Smirk - vinanet.vn

Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan

Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm

Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com

Why Is Femasys Stock Soaring Today? - Femasys (NASDAQ:FEMY) - Benzinga

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits

FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - TradingView

Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria

Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current Session - Low Growth Earnings - Vinanet

Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance

Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com

FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan

Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com India

Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record

Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - marketscreener.com

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Yahoo Finance

Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current Session - Analyst Coverage Count - dars.gov.et

Femasys secures $30 million to advance fertility portfolio - The Pharma Letter

Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan

FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31% - Earnings Turnaround - vinanet.vn

Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo

Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us

Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade

Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan

FEMY와(과) 유사한 종목